Inflammation promotes erythropoietin induced vascular calcification by activating p38 pathway

References

• Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate [J]. Circ Res. 2011;109(6):697–711.
   PubMed Web of Science ®Google Scholar
• Singh B, Núñez NA, Schock L, et al. Lithium continuation for a patient with bipolar disorder and chronic kidney disease [J]. Bipolar Disord. 2020;22(3):316–318.
   PubMed Web of Science ®Google Scholar
• Pande SD, and Morris J. Influence of chronic kidney disease and haemodialysis on stroke outcome [J]. Singapore Med J. 2020;62(11): 594–598 .
   PubMed Web of Science ®Google Scholar
• Stremke ER, Biruete A, Hill Gallant KM. Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease [J]. Curr Osteoporos Rep. 2020;18(3):247–253.
   PubMed Web of Science ®Google Scholar
• Widén J, Ivarsson M, Schalin L, et al. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden [J]. Pharmacoeconomics. 2020;38(7):747–764.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients [J]. Am J Kidney Dis. 2004;44(5):866–876.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes [J]. Kidney Int. 2008;74(6):791–798.
   PubMed Web of Science ®Google Scholar
• Inrig JK, Barnhart HX, Reddan D, et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial [J]. Am J Kidney Dis. 2012;60(3):390–401.
   PubMed Web of Science ®Google Scholar
• Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis [J]. Am J Kidney Dis. 2013;61(1):44–56.
   PubMed Web of Science ®Google Scholar
• Berns JS. Should all patients with chronic kidney disease receive an EPO-type drug? [J]. Cleve Clin J Med. 2006;73(3):298–300.
   PubMed Web of Science ®Google Scholar
• Belonje AM, de Boer RA, Voors AA. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: “Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.” [J]. Cardiovasc Drugs Ther. 2008;22(1):1–2.
   PubMedGoogle Scholar
• Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss [J]. Science. 2010;329(5990):407.
   PubMed Web of Science ®Google Scholar
• Patel JJ, Bourne LE, Davies BK, et al. Differing calcification processes in cultured vascular smooth muscle cells and osteoblasts [J]. Exp Cell Res. 2019;380(1):100–113.
   PubMed Web of Science ®Google Scholar
• Hénaut L, Chillon JM, Kamel S, et al. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease [J]. Semin Nephrol. 2018;38(3):233–250.
   PubMed Web of Science ®Google Scholar
• Li X, Jiang X, He F, et al. Effect of Erythropoietin on Calcification of Vascular Smooth Muscle Cells and Its Molecular Regulatory Mechanism [J]. J Cardiovasc Transl Res. 2021;14(3):525–537.
   PubMed Web of Science ®Google Scholar
• He J, Zhong X, Zhao L, et al. JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells [J]. Clin Exp Nephrol. 2019;23(4):501–512.
   PubMed Web of Science ®Google Scholar
• Zhou R, Miao S, Xu J, et al. Circular RNA circ_0000020 promotes osteogenic differentiation to reduce osteoporosis via sponging microRNA miR-142-5p to up-regulate Bone Morphogenetic Protein BMP2 [J]. Bioengineered. 2021;12(1):3824–3836.
   PubMed Web of Science ®Google Scholar
• Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease [J]. Kidney Int Suppl. 2008;111:S4–9.
   PubMed Web of Science ®Google Scholar
• Shao JS, Cheng SL, Sadhu J, et al. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective [J]. Hypertension. 2010;55(3):579–592.
   PubMed Web of Science ®Google Scholar
• Amdur RL, Feldman HI, Gupta J, et al. Inflammation and Progression of CKD: the CRIC Study [J]. Clin J Am Soc Nephrol. 2016;11(9):1546–1556.
   PubMed Web of Science ®Google Scholar
• Jia Y, Xu H, Yu Q, et al. Identification and verification of vascular cell adhesion protein 1 as an immune-related hub gene associated with the tubulointerstitial injury in diabetic kidney disease [J]. Bioengineered. 2021;12(1):6655–6673.
   PubMed Web of Science ®Google Scholar
• Mihai S, Codrici E, Popescu ID, et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome [J]. J Immunol Res. 2018;2018:2180373.
   PubMed Web of Science ®Google Scholar
• Glorieux G, Gryp T, Perna A. Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease [J]. Toxins (Basel). 2020;12(4):245.
   PubMed Web of Science ®Google Scholar
• Towler DA. Oxidation, inflammation, and aortic valve calcification peroxide paves an osteogenic path [J]. J Am Coll Cardiol. 2008;52(10):851–854.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhong S, Qu H, et al. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice [J]. Sci Rep. 2015;5(1):10222.
   PubMedGoogle Scholar
• Ji J, Feng M, Niu X, et al. Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR) [J]. Bioengineered. 2021;12(1):8057–8066.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Iwasaki H, Masuda I, et al. The utility of alizarin red s staining in calcium pyrophosphate dihydrate crystal deposition disease [J]. J Rheumatol. 2003;30(5):1032–1035.
   PubMed Web of Science ®Google Scholar
• Rastogi RP, Singh SP, Häder DP, et al. Detection of reactive oxygen species (ROS) by the oxidant-sensing probe 2’,7’-dichlorodihydrofluorescein diacetate in the cyanobacterium Anabaena variabilis PCC 7937 [J]. Biochem Biophys Res Commun. 2010;397(3):603–607.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Posch A. The design of a quantitative Western blot experiment [J]. Biomed Res Int. 2014;2014:361590.
   PubMed Web of Science ®Google Scholar
• Donaldson JG. Immunofluorescence Staining [J]. Curr Protoc Cell Biol. 2015;69(1):4.3.1–4.3.7.
   PubMedGoogle Scholar
• Li C, Zhang S, Chen X, et al. Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p [J]. Commun Biol. 2020;3(1):327.
   PubMed Web of Science ®Google Scholar
• Foskett A, Alnaeeli M, Wang L, et al. The Effects of Erythropoietin Dose Titration during High-Fat Diet-Induced Obesity [J]. J Biomed Biotechnol. 2011;2011:373781.
   PubMedGoogle Scholar
• Mei M, Zhao L, Li Q, et al. Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice [J]. Lipids Health Dis. 2011;10(1):110.
   PubMedGoogle Scholar
• Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling [J]. J Biol Chem. 2008;283(22):15319–15327.
   PubMed Web of Science ®Google Scholar
• Zickler D, Luecht C, Willy K, et al. Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression [J]. Nephrol Dial Transplant. 2018;33(4):574–585.
   PubMed Web of Science ®Google Scholar
• Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway [J]. Circulation. 2000;102(21):2636–2642.
   PubMed Web of Science ®Google Scholar
• Xu K, Huang Y, Zhou T, et al. Nobiletin exhibits potent inhibition on tumor necrosis factor alpha-induced calcification of human aortic valve interstitial cells via targeting ABCG2 and AKR1B1 [J]. Phytother Res. 2019;33(6):1717–1725.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Smith KE, Koller A, et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure [J]. Circulation. 2005;111(18):2364–2372.
   PubMed Web of Science ®Google Scholar
• Chang JR, Sun N, Liu Y, et al. Erythropoietin attenuates vascular calcification by inhibiting endoplasmic reticulum stress in rats with chronic kidney disease [J]. Peptides. 2020;123:170181.
   PubMed Web of Science ®Google Scholar
• Yao Y, Watson AD, Ji S, et al. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein [J]. Circ Res. 2009;105(6):575–584.
   PubMed Web of Science ®Google Scholar
• de Alvaro C, Teruel T, Hernandez R, et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner [J]. J Biol Chem. 2004;279(17):17070–17078.
   PubMed Web of Science ®Google Scholar
• Nöth U, Tuli R, Seghatoleslami R, et al. Activation of p38 and Smads mediates BMP-2 effects on human trabecular bone-derived osteoblasts [J]. Exp Cell Res. 2003;291(1):201–211.
   PubMed Web of Science ®Google Scholar